Drug Trial Radar · NCT07020923
Monthly Dosing of Atacicept in IgAN
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
May 29, 2025
Primary completion
Sep 22, 2026
Study completion Sep 2027
Sponsor
- Lead sponsor
- Vera Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept
Conditions
- IgA Nephropathy (IgAN)
- Berger Disease
Interventions
AtaciceptDrug
Drug: Atacicept
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the effect of atacicept on Gd-IgA1 in patients with IgANTime frame: Up to 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vera Therapeutics
Brisbane, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.